MS2 VLP-based delivery of microRNA-146a inhibits autoantibody production in lupus-prone mice

Background Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by the presence of pathogenic autoantibodies. Recent studies suggest that microRNAs (miRNAs) play an essential role in immunoregulation and may be involved in the pathogenesis of SLE. Therefore, it was of interest to investigate the potential therapeutic application of miRNAs in SLE, a concept that has not been thoroughly investigated thus far. Virus-like particles (VLPs) are a type of recombinant nanoparticle enveloped by certain proteins derived from the outer coat of a virus. Herein, we describe a novel miRNA-delivery approach via bacteriophage MS2 VLPs and investigate the therapeutic effects of miR-146a, a well-studied and SLE-related miRNA, in BXSB lupus-prone mice. Methods VLPs containing miR-146a, and the control VLPs, were prepared using an Escherichia coli expression system and then administered to lupus-prone mice over a 12-day period. We performed an enzyme-linked immunosorbent assay to evaluate the anti-dsDNA antibody, autoantibody to nuclear antigen (ANA), total IgG and total IgM levels in serum. The expression of miR-146a was analyzed by qRT-PCR. SLE-related cytokines as well as some toll-like receptor signaling pathway molecules were also measured. Results Treatment with MS2-miR146a VLP showed profound effects on lupus-prone BXSB mice, including an increased level of mature miR-146a, which led to a significant reduction in the expression of autoantibodies and total IgG. Remarkably, these mice also exhibited reduced levels of proinflammatorycytokines, including IFN-Interferon-α (IFN-α), Interleukin-1β (Il-1β) and Interleukin-6 (Il-6). Moreover, we showed that the toll-like receptor pathway was involved in this regulation. Conclusion Restoring the loss of miR-146a was effective in eliminating the production of autoantibodies and ameliorating SLE progression in lupus-prone mice. Thus, the induction of dysregulated miRNAs by an MS2 VLP-based delivery system may lead to novel therapies.

[1]  Beverly L. Davidson,et al.  Current prospects for RNA interference-based therapies , 2011, Nature Reviews Genetics.

[2]  O. Crasta,et al.  Identification of a Common Lupus Disease-Associated microRNA Expression Pattern in Three Different Murine Models of Lupus , 2010, PloS one.

[3]  L. Fossati-Jimack,et al.  Lessons from BXSB and Related Mouse Models , 2000, International reviews of immunology.

[4]  Scott E. Martin,et al.  MicroRNAs and genomic instability. , 2007, Seminars in Cancer Biology.

[5]  S. Ahmed,et al.  MicroRNA, a new paradigm for understanding immunoregulation, inflammation, and autoimmune diseases. , 2011, Translational research : the journal of laboratory and clinical medicine.

[6]  N. Rajewsky,et al.  Widespread changes in protein synthesis induced by microRNAs , 2008, Nature.

[7]  Wei Wang,et al.  Development of an antisense RNA delivery system using conjugates of the MS2 bacteriophage capsids and HIV-1 TAT cell-penetrating peptide. , 2009, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[8]  S. Kauppinen,et al.  Silencing of microRNA-21 in vivo ameliorates autoimmune splenomegaly in lupus mice , 2011, EMBO molecular medicine.

[9]  P. Linsley,et al.  miR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice , 2011, The Journal of experimental medicine.

[10]  Kaleb M. Pauley,et al.  miR-146a Is Critical for Endotoxin-induced Tolerance , 2009, The Journal of Biological Chemistry.

[11]  P. Lipsky,et al.  Rationale for interleukin-6 blockade in systemic lupus erythematosus , 2004, Lupus.

[12]  J. Shupe,et al.  TLR9 Regulates TLR7- and MyD88-Dependent Autoantibody Production and Disease in a Murine Model of Lupus , 2010, The Journal of Immunology.

[13]  B. Diamond,et al.  Current and novel therapeutics in the treatment of systemic lupus erythematosus , 2011 .

[14]  S. Schokrpur,et al.  Expression of microRNA-146 suppresses NF-κB activity with reduction of metastatic potential in breast cancer cells , 2008, Oncogene.

[15]  S. Santoro,et al.  A Three-dimensional Collagen Lattice Activates NF-κB in Human Fibroblasts: Role in Integrin α2 Gene Expression and Tissue Remodeling , 1998, The Journal of cell biology.

[16]  P. Tak,et al.  MicroRNA-146A contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins. , 2009, Arthritis and rheumatism.

[17]  Igor M. Dozmorov,et al.  Identification of Unique MicroRNA Signature Associated with Lupus Nephritis , 2010, PloS one.

[18]  L. Morel,et al.  Murine Models of Systemic Lupus Erythematosus , 2011, Journal of biomedicine & biotechnology.

[19]  Ajit S. Narang,et al.  Subcellular Fate and Off-Target Effects of siRNA, shRNA, and miRNA , 2011, Pharmaceutical Research.

[20]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[21]  Kaleb M. Pauley,et al.  Upregulated miR-146a expression in peripheral blood mononuclear cells from rheumatoid arthritis patients , 2008, Arthritis research & therapy.

[22]  Xi-sha Chen,et al.  MicroRNA‐146a and Human Disease , 2010, Scandinavian journal of immunology.

[23]  M. Shlomchik,et al.  Chromatin–IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors , 2002, Nature.

[24]  V. Kelley,et al.  Biphasic increase in circulating and renal TNF-alpha in MRL-lpr mice with differing regulatory mechanisms. , 1995, Kidney international.

[25]  Jacob M Hooker,et al.  Dual-surface-modified bacteriophage MS2 as an ideal scaffold for a viral capsid-based drug delivery system. , 2007, Bioconjugate chemistry.

[26]  Y. Shoenfeld,et al.  Autoantibody explosion in systemic lupus erythematosus: more than 100 different antibodies found in SLE patients. , 2004, Seminars in arthritis and rheumatism.

[27]  A. Pasquinelli,et al.  Regulation by let-7 and lin-4 miRNAs Results in Target mRNA Degradation , 2005, Cell.

[28]  V. Pascual,et al.  Type I interferon in systemic lupus erythematosus and other autoimmune diseases. , 2006, Immunity.

[29]  W. Brown,et al.  Delivery of antisense oligonucleotides to leukemia cells by RNA bacteriophage capsids. , 2005, Nanomedicine : nanotechnology, biology, and medicine.

[30]  E. Chan,et al.  MicroRNAs in systemic rheumatic diseases , 2011, Arthritis research & therapy.

[31]  D. Brennan,et al.  Tumor necrosis factor and IL-1 in New Zealand Black/White mice. Enhanced gene expression and acceleration of renal injury. , 1989, Journal of immunology.

[32]  Yuan Zhang,et al.  Development of a microRNA delivery system based on bacteriophage MS2 virus‐like particles , 2012, The FEBS journal.

[33]  L. Klareskog,et al.  Cytokine production, serum levels and disease activity in systemic lupus erythematosus. , 2000, Clinical and experimental rheumatology.

[34]  J. Au,et al.  Delivery of siRNA Therapeutics: Barriers and Carriers , 2010, The AAPS Journal.

[35]  A. Marshak‐Rothstein.  Toll-like receptors in systemic autoimmune disease , 2006, Nature Reviews Immunology.

[36]  B. Beutler,et al.  Endosomal TLR signaling is required for anti-nucleic acid and rheumatoid factor autoantibodies in lupus , 2009, Proceedings of the National Academy of Sciences.

[37]  L. Pasquier,et al.  Orphanet Journal of Rare Diseases , 2006 .

[38]  Yong Dai,et al.  Comprehensive analysis of microRNA expression patterns in renal biopsies of lupus nephritis patients , 2009, Rheumatology International.

[39]  Praveen Sethupathy,et al.  MicroRNA target site polymorphisms and human disease. , 2008, Trends in genetics : TIG.

[40]  M. Francis,et al.  Oxidative coupling of peptides to a virus capsid containing unnatural amino acids. , 2008, Chemical communications.

[41]  M. Cleary,et al.  Comparative assessment of siRNA and shRNA off target effects: what is slowing clinical development , 2009, Cancer Gene Therapy.